Af de 806 infusioner til patienterne i begge studier fremkaldte 10, 8% (ensidet 95% CI øvre grænse = 12, 9%) en bivirkning, der antages at være knyttet til præparatet.
Of the 806 infusions administered in patients enrolled in both studies 10.8% (1-sided 95% CI upper bound = 12.9%) were associated with an adverse event suspected to be related to the product.